Core Viewpoint - UnitedHealth Group is facing challenges with rising medical costs and utilization, leading to a lowered earnings guidance for 2025, but its diversified business model and vertical integration provide resilience in a tough market [1][9][10]. Financial Performance - For Q1 2025, UnitedHealth reported earnings per share (EPS) of $7.20, missing consensus estimates by $0.09, while revenues grew 9.8% year-over-year to $109.58 billion, falling short of the $111.58 billion consensus [5]. - The Optum subsidiary generated 42% of the company's operating profits, with Q1 revenue of $63.9 billion, up 4.4% year-over-year [6]. - The medical care ratio (MCR) was reported at 84.8%, slightly up from 84.3% in Q1 2024, indicating a strong cost containment strategy [7]. Market Position and Sentiment - Despite negative sentiment towards health insurers due to rising costs, UnitedHealth is viewed as the best option in a challenging environment due to its integrated healthcare model [4]. - The stock has seen fluctuations, recovering from a low of $425.39 to a high of $606.36 in April 2025, but has recently faced a downturn due to lowered earnings guidance [2][16]. Future Outlook - The company has adjusted its full-year 2025 EPS guidance to a range of $26.00 to $26.50, significantly lower than the previous consensus of $29.72, primarily due to increased medical care activity [9]. - Management remains optimistic about growth, particularly in OptumRx, and anticipates an increase in Medicare Advantage (MA) plan membership by 800,000 in 2025 [10][13]. - The Center for Medicare and Medicaid Services (CMS) announced a 5.06% increase in MA plan reimbursements for 2026, which could serve as a positive catalyst for the company [12].

Financial Data and Key Metrics Changes - In Q1 2025, GAAP diluted earnings per share was $9.61, and adjusted diluted earnings per share was $11.97, reflecting year-over-year growth of more than 10% [25] - Operating revenue for the quarter was $48.8 billion, an increase of over 15%, driven by higher premium yields in the health benefits segment and growth in Medicare Advantage and individual ACA membership [26] - The consolidated benefit expense ratio was 86.4%, an increase of 80 basis points year over year, primarily due to higher cost trends in the Medicaid business [27] Business Line Data and Key Metrics Changes - Medicaid business is making progress on rate alignment, with April adjustments coming in as expected [16] - Medicare Advantage performance was consistent with expectations, with strong retention and targeted growth [17] - Health benefits operating gain was $2.2 billion, slightly declining due to higher Medicaid costs, while Calon's operating gain grew 34% to $1.1 billion [29] Market Data and Key Metrics Changes - Individual ACA membership grew approximately 11% sequentially, but a moderation in membership is anticipated in Q2 due to lower effectuation rates [25][56] - The company is expanding into three new states to support broader strategy for coordinated ACA and Medicaid coverage [19] Company Strategy and Development Direction - The company is focused on transforming healthcare experiences to be simpler, more affordable, and more human, with sustained investments in patient advocacy solutions and digital platforms [9][10] - Expansion of value-based oncology care model to Medicare Advantage is planned, following success in the commercial sector [12] - Carillon continues to be a strategic growth engine, significantly expanding relationships with external payers [20] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for Medicare Advantage, emphasizing strong retention and disciplined growth [17] - Elevated Medicare costs are manageable, with consistent tracking of claims data to identify emerging patterns [39][41] - The company remains disciplined in its approach to benefit design and risk management, ensuring alignment with healthcare needs [129] Other Important Information - The company was named to Fortune's 100 Best Companies to Work For and recognized as one of America's most innovative companies [22] - Operating cash flow totaled $1 billion, with expectations for approximately $8 billion for the year remaining unchanged [32] Q&A Session Summary Question: Medicare Advantage trends and IRA impact - Management indicated that Medicare costs remain elevated but manageable, with no material changes in expectations [39][41] Question: Carillon Services growth and cross-sales - Carillon Services experienced over 60% growth, with strong internal and external expansion [47] Question: Effectuation rates and membership attrition - Membership attrition is projected in the mid-single digit percent range in early Q2, with stabilization expected thereafter [56] Question: Medicaid MLR margin trends - Medicaid trends remain elevated but decelerated as expected, with improvements anticipated in the latter half of the year [117] Question: Part D changes and utilization behavior - Management is comfortable with the mix of Medicare Advantage membership and has not observed substantial variations in utilization [140]

• Rollins, Inc. achieved annual savings of approximately $7.7 million, allowing the company to reinvest in strategic business initiatives and employee wellness, including on-site clinics. • Analysis included members across 47 states. Rising healthcare costs are posing a major challenge for self-funded employers, with PwC forecasting an 8% increase in 2025 – the highest rate in thirteen years. Imagine360 achieves measurable cost savings and industry- leading member satisfaction by delivering a fundamentally ...

I have not written to you about UnitedHealth Group Incorporated (NYSE: UNH ) before, though over time I have owned a modest on-and-off position in the stock.Individual investor focused upon a limited number of diversified stocks. Seeks stocks selling below fair value estimates; favors dividend growth and/or income. Advocates fundamental investment analysis, supplemented by the technical charts. Options strategies primarily employed to generate additional income or hedge risk. If interested, you may find out ...

Core Insights - UnitedHealth Group (UNH) reported disappointing first-quarter 2025 results, missing both earnings and revenue estimates, and lowered its full-year guidance due to rising medical costs, leading to a significant decline in its stock price [1][2] - The company's shares fell 22.4% following the results, marking the worst daily decline since 1998 and erasing approximately $120 billion from its market capitalization, although this decline may present a long-term buying opportunity [2] Earnings Performance - Earnings per share (EPS) were reported at $7.20, missing the Zacks Consensus Estimate of $7.27 but showing a 4.2% increase from the previous year's EPS of $6.16 [4] - Revenues grew by 9.8% year-over-year to $109.6 billion, falling short of the estimated $111.1 billion [4] - Optum revenues increased by 4.6% to $63.9 billion, while the medical ratio rose by 0.5 percentage points year-over-year to 84.8%, with management forecasting a ratio of 87%-88% for 2025 [4][6] Consumer Growth - The number of consumers served with self-funded commercial benefits increased by approximately 700,000 in the first quarter, and the number of seniors and complex needs patients served grew by 545,000, expected to reach 800,000 in 2025 [5] - The company's state-based community plans now serve 7.6 million members, and Optum Health anticipates serving 650,000 new value-based care patients in 2025 [5] Guidance Adjustments - UnitedHealth reaffirmed its revenue guidance for 2025 at $450-$455 billion but reduced its EPS guidance to $26.00-$26.50 from a previous range of $29.50-$30.00, citing increased care activity in Medicare Advantage and impacts from Medicare funding reductions [6] ETF Opportunities - Investors may consider ETFs with significant allocations to UnitedHealth, including iShares U.S. Healthcare Providers ETF (IHF), Health Care Select Sector SPDR Fund (XLV), JPMorgan Healthcare Leaders ETF (JDOC), Fidelity MSCI Health Care Index ETF (FHLC), and iShares U.S. Healthcare ETF (IYH) [3]

Market Overview - The CNN Money Fear and Greed index remained in the "Extreme Fear" zone with a current reading of 20.9, down from 21.4 [7][8] - U.S. stocks mostly settled lower, with the Dow Jones index falling over 500 points, marking its third consecutive day of losses [1][5] Company Performance - UnitedHealth Group Incorporated (UNH) shares dropped over 22% after reporting worse-than-expected first-quarter results and lowering its FY25 adjusted EPS guidance [2] - Nvidia Corp. (NVDA) shares fell approximately 3% after a prior decline of around 7% [2] - Eli Lilly & Co. (LLY) shares experienced their sharpest single-day rally in nearly 25 years following positive data from a pivotal trial for a weight-loss drug, with the market for such drugs projected to triple by 2030 [3] Economic Data - U.S. housing starts decreased by 11.4% month-over-month to an annualized rate of 1.324 million in March [4] - Initial jobless claims fell by 9,000 to 215,000, better than market estimates of 225,000 [4] - The Philadelphia Fed Manufacturing Index dropped 39 points to -26.4, significantly below market expectations of 2 [4] Sector Performance - Most sectors on the S&P 500 closed positively, with energy, consumer staples, and real estate stocks showing the largest gains [5] - Information technology and health care sectors closed lower, contrasting with the overall market trend [5]

Core Insights - UnitedHealth (NYSE: UNH) experienced its 4th largest one-day stock drop in history, indicating significant market volatility and investor concern [1] Company Analysis - The decline in UnitedHealth's stock price suggests potential underlying issues that may need further investigation to understand the causes and implications for future performance [1] Market Context - The stock market environment appears to be volatile, which may present both risks and opportunities for investors, particularly in the context of options trading and delta neutral strategies [1]

Group 1 - The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of UnitedHealth Group due to allegations of materially misleading business information [1] - UnitedHealth's stock fell 22.3% on April 17, 2025, after the company reported earnings that fell short of Wall Street's expectations and downgraded its projected results for 2025, citing issues in its Medicare business [3] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses, allowing affected shareholders to join without any out-of-pocket fees through a contingency fee arrangement [2] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] - The founding partner of the firm was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3]

Core Viewpoint - UnitedHealth Group Inc. reported mixed first-quarter 2025 results, with adjusted EPS of $7.20 falling short of estimates, while revenues increased year over year but missed consensus expectations due to lower premiums [1][2]. Financial Performance - Adjusted EPS for Q1 2025 was $7.20, missing the Zacks Consensus Estimate of $7.27, but reflecting a 4.2% year-over-year increase [1]. - Revenues rose 9.8% year over year to $109.58 billion, but missed the consensus mark by 1.4% [1]. - Medical care ratio (MCR) was 84.8%, worsening from 84.3% a year ago and below the consensus estimate of 85.9% [4]. - Total operating costs increased 9.4% year over year to $100.5 billion, exceeding model estimates [5]. - Operating earnings grew 15% year over year to $9.1 billion, with net margin improving from negative 1.4% to 5.7% [6]. Business Segment Performance - UnitedHealthcare revenues increased 12.3% year over year to $84.6 billion, driven by domestic commercial membership growth, surpassing estimates [7]. - Optum revenues were $63.9 billion, up 4.6% year over year, but fell short of the consensus mark [8]. - UnitedHealthcare served 50.1 million members, a 1.9% year-over-year growth, but below the consensus estimate of 50.6 million [9]. Financial Position - Cash and short-term investments rose to $34.3 billion from $29.1 billion at the end of 2024 [10]. - Total assets increased to $309.8 billion from $298.3 billion at the end of 2024 [11]. - Long-term debt decreased to $71.29 billion from $72.36 billion [11]. - Operating cash flows surged to $5.5 billion from $1.1 billion year over year [12]. Capital Deployment - UnitedHealth returned over $5 billion to shareholders through share repurchases and dividends in Q1 2025 [13]. 2025 Outlook - Management revised adjusted net EPS guidance to between $26 and $26.50, down from previous estimates [14]. - Projected net earnings for 2025 are expected to be between $22.5 billion and $23.1 billion, an increase from 2024 [14]. - Revenue estimates for 2025 are between $450 billion and $455 billion, up from $400.3 billion in 2024 [14].

Financial Data and Key Metrics Changes - The company revised its adjusted earnings per share outlook for 2025 to $26 to $26.50, reflecting performance challenges primarily in its Medicare businesses [7][29] - The consolidated revenue outlook remains at $450 billion to $455 billion, with expectations for UnitedHealthcare and Optum Rx revenues to exceed initial views, offsetting a reduced outlook for Optum Health [30][31] - The full year medical care ratio is now expected to be 87.5% plus or minus 50 basis points, indicating higher utilization across senior populations [31] Business Line Data and Key Metrics Changes - UnitedHealthcare's Medicare Advantage business is projected to serve an additional 800,000 people in 2025, while Optum Health aims to add 650,000 net new patients to value-based care arrangements [16][43] - Optum Rx revenues grew by 14%, exceeding $35 billion for the quarter, with script growth of 3% driven by customer retention and new customer wins [44] Market Data and Key Metrics Changes - The company noted a significant increase in care activity in its Medicare Advantage business, with first quarter indications suggesting care activity increased at twice the rate anticipated [10][29] - The company experienced a sharp increase in elective care activity, particularly in the group Medicare Advantage segment, attributed to higher member premiums driven by Medicare funding cuts [36][66] Company Strategy and Development Direction - The company is focusing on improving engagement with complex patients and enhancing clinical workflows to transition effectively to the new CMS risk model [15][39] - The company continues to innovate in its service offerings, such as the HouseCalls program, which provides in-home clinical visits to seniors [21][22] - The company emphasizes the importance of transparency and affordability in healthcare, aiming to reduce costs for consumers while maintaining high-quality care [28][132] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with current performance but remains committed to improving results throughout 2025 and into 2026, targeting long-term earnings per share growth of 13% to 16% [46][47] - The management acknowledged the challenges posed by recent Medicare funding cuts and the need to better anticipate and address second-order effects in the market [90][96] Other Important Information - The company is actively engaging with state customers to address Medicaid funding issues and is optimistic about recent rate adjustments aligning more closely with member acuity [41][130] - The company is concerned about legislative changes affecting pharmacy benefit managers (PBMs) and their potential impact on patient access to medications [126][127] Q&A Session Summary Question: Medicare Advantage cost trend expectations - Management indicated that care levels were anticipated to be consistent with 2024 but have seen a significant increase in the first quarter, particularly in physician and outpatient services [49][55] Question: Connection between primary care visits and Optum Health performance - Management clarified that while primary care visits have increased, the challenges in Optum Health are due to the profile of new value-based patients and the impact of the V28 phase [58][68] Question: Impact of elevated care on group Medicare Advantage - Management confirmed that the elevated care activity is primarily observed in community and group Medicare Advantage, influenced by premium increases [98][102] Question: Long-term growth rate recovery - Management expressed confidence in returning to long-term growth rates, supported by improved 2026 rates and ongoing engagement with state partners [106][110] Question: Medicare Advantage margins and timeline for recovery - Management stated that margins for Medicare Advantage are still within targeted ranges for 2025, with expectations to return to historical planning targets in 2026 [114][118] Question: Policy implications of PBM reform and Medicaid funding - Management highlighted their leadership in transparency and affordability in the PBM space and emphasized the importance of maintaining access to medications for patients [122][130]